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ABSTRACT 
EFFECTS OF CALCIUM CHANNEL BLOCKADE 
ON 
CATECHOLAMINE CARDIOMYOPATHY 
Virginia Shau Shen Huang 
1985 
The catecholamines have long been known to cause car¬ 
diac injury when delivered in high concentrations. Patho¬ 
genetic mechanisms have been much debated and remain unre¬ 
solved. Those receiving most attention include ischemic 
injury resulting from coronary vasoconstriction or excessive 
metabolic demand, and direct membrane injury causing break¬ 
down of critical ion exchange mechanisms. Excessive calcium 
accumulation within the myocyte is frequently found and 
viewed as a lethal consequence of this process. Whether it 
is causal, or the result of other pathways leading to mem¬ 
brane damage is presently unresolved. To provide further 
insight into the role of calcium exchange as a significant 
factor in myocyte injury, experiments were undertaken to 
determine if a recognized calcium channel blocking agent 
(verapamil) was capable of altering the pattern of myocar¬ 
dial damage known to result from norepinephrine administra¬ 
tion in a rabbit model. 
■ 
New Zealand white rabbits were anesthetized with pen¬ 
tobarbital (30 mg/kg), and cannulas placed in the femoral 
artery and vein. They were then subjected to various 90 
minute infusion protocols. These included norepinephrine, 2 
or 3 ug/kg/min (NE-2, NE-3). Other groups were given a 50 
ug loading dose of verapamil (VE), followed by infusions of 
NE-2 or NE-3 with concomitant infusions of verapamil, 1 or 2 
ug/kg/min (VE-1, VE-2). Two to three days later, the rab¬ 
bits were sacrificed, the hearts examined microscopically 
and assigned a histologic score. Administration of verapa¬ 
mil simultaneously with norepinephrine significantly reduced 
the histologic injury score from 1.24 _+ 0.10 (NE-2) to 0.59 
+ 0.13 (NE-2 + VE-1, p<0.01) and 0.65 + 0.10 (NE-2 + VE-2, 
p<0.01). VE-2 infusion was also protective against a higher 
dose of norepinephrine at 3 ug/kg/min (NE-3), reducing the 
histologic score from 1.44 + 0.13 (NE-3) to 0.69 + 0.21 (NE- 
3 + VE-2, p<0.01). A higher dose of verapamil did not 
result in a substantial increase in protection as the histo¬ 
logic scores of the VE-1 and VE-2 groups were not signifi¬ 
cantly different. Administration of verapamil did not sub¬ 
stantially lower the pressure-rate product (an index of 
metabolic demand) during norepinephrine infusion nor did it 
significantly diminish the norepinphrine-induced rise in 
systemic blood pressure. Thus, afterload reduction was not 
a significant mechanism. Arterial pH, arterial blood gases, 
plasma glucose, and hematocrit were unaltered by verapamil 
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infusion. It is concluded that verapamil significantly 
reduces myocardial damage produced by norepinephrine infu¬ 
sion in the rabbit and the mechanism of protection probably 
does not involve verapamil-induced reductions in afterload 
or cardiac metabolic demand. Verapamil may act by preven¬ 
tion of norepinephrine-induced coronary vasoconstriction, 
inhibition of myocardial alpha receptor activation, or pre¬ 
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It has been known since the early 1900's that catechol¬ 
amines can injure the heart. The agents that have been 
studied most extensively are epinephrine, norepinephrine, 
and isoproterenol. Epinephrine was the first one to be 
found to have cardiotoxic effects. In his review of cate¬ 
cholamine-induced cardiomyopathy, Haft (1) describes a clas¬ 
sic 1905 study in which Ziegler (2) found intramyocardial 
hemorrhage, edema, patchy areas of myofibrillar damage, 
round cell infiltration, and proliferation of fibrous tissue 
in the hearts of rabbits injected with epinephrine. Fleisher 
and Loeb (3) in 1909 produced myocarditis in the rabbit with 
epinephrine alone or in combination with sparteine or caf¬ 
feine. Similar cardiac lesions were reported by Christian 
et al in 1911 in studies involving the effects of epineph¬ 
rine injections on the production of renal and cardiac 
injury (4). 
Following these earlier studies, numerous investigators 
have been able to confirm the cardiotoxicity of epinephrine 
(5-10). It is interesting to note that although the pharma¬ 
cological properties of norepinephrine were described by 
Barger and Dale in 1910 (11), and its presence in tissues 
demonstrated in 1946 when Von Euler (12) isolated it from 
adrenergic nerve fibers, it was not until 1958 that norepi¬ 
nephrine was demonstrated to be cardiotoxic. Szakacs et al 
(13) infused norepinephrine into dogs and found large suben¬ 
docardial and myocardial hemorrhages in both ventricles, the 
right atrium, and the mitral valve. There were also multi- 
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pie focal lesions without apparent preferential distri¬ 
bution. The myocardial lesions were identical to those 
caused by epinephrine in rabbits and manifested edema, endo¬ 
cardial fibroblastic proliferation, degenerating myofibrils, 
and cellular infiltration (3,4). The cardiotoxic effects of 
norepinephrine infusion were further documented by Maling 
(7,14) in 1958 and 1960. They found fatty changes in the 
myocardium of dogs one to three days after infusion with 
norepinephrine. Focal necrosis, hemorrhages, and round cell 
infiltration of the myocardium were also present. Nahas (6) 
found in 1958 that infusions of norepinephrine in heart-lung 
preparations of dogs which isolated the heart from all 
secondary or neural influences caused extensive degeneration 
and hemorrhagic lesions of the myocardium, cardiac valves, 
and the appearance of coronary lesions. Rosenblum et al in 
1965 (9) reported that three consecutive intraperitoneal in¬ 
jections of norepinephrine made at 24 hour intervals pro¬ 
duced interstitial edema and mononuclear cell infiltration 
that was less severe than damage caused by isoproterenol at 
comparable doses. 
Schenk and Moss (15) in 1966 infused norepinephrine 
into dogs, cats, and rabbits with doses comparable to those 
used clinically and found cardiac lesions in all the ani¬ 
mals. These consisted of focal degeneration and necrosis of 
myofibers and subendocardial hemorrhages. Rabbits were most 
susceptible while dogs were the least susceptible to the 
development of cardiac lesions. The authors were also able 
to establish dose-response relationships. 
Similarly, Hoak (16) in 1969 found that intravenous 
- 
3 
infusions of norepinephrine for six hours in dogs produced 
elevated plasma free fatty acid (FFA) concentrations and 
hemorrhagic lesions in the subendocardial portions of the 
left ventricle with areas of myofibrillar necrosis, edema, 
and polymorphonuclear infiltration. Electron microscopy 
showed extensive destruction of myofibrils and mitochondria 
and the presence of osmiophilic inclusions within the mito¬ 
chondria . 
Shortly after norepinephrine was discovered to be car- 
diotoxic, Chappel and Rona et al (17) demonstrated in 1959 
that isoproterenol, a synthetic adrenergic agent, adminis¬ 
tered subcutaneously to the rat caused infarct-like myocar¬ 
dial necrosis and that the severity of the lesions was 
directly proportional to the damage. Thus lesions of pre¬ 
dictable severity could be produced. They also showed that 
the lesions seen after isoproterenol treatment were more 
severe than those produced by epinephrine and norepinephrine 
(8). The synthetic and exogenous isoproterenol has since 
then been used extensively in studies of catecholamine- 
induced cardiomyopathy (18-26). 
Excess catecholamines secreted in stressful situations 
or in pheochromocytomas have been shown to result in myocar¬ 
dial damage. Szakacs and Cannon (13) found in 1958 that 
patients who received prolonged norepinephrine infusions for 
shock, and patients with pheochromocytoma had similar car¬ 
diac lesions to those produced in the dog by prolonged 
norepinephrine infusions in amounts comparable to therapeu¬ 
tic dosages. The lesions consisted of focal myocardial ne- 
■ 
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crosis, inflammatory exudate, and epicardial hemorrhage. 
Kline (26) in 1961 reported autopsy findings from pa¬ 
tients with pheochromocytomas and found that these myocar¬ 
dial lesions resembled those in experimental animals treated 
with norepinephrine. These consisted primarily of severe 
degenerative changes in groups of muscle fibers, foci of 
necrosis, and chronic interstitial inflammatory exudation. 
Van Vliet et al (27) in 1966 compared autopsy findings 
of patients with pheochromocytomas and those produced by a 
series of subcutaneous injections of norepinephrine in rats. 
Fifteen of twenty-six patients manifested "active catechol¬ 
amine myocarditis". The lesions were characterized by focal 
degeneration and necrosis of myocardial fibers with foci of 
inflammatory cells that were predominantly histiocytes, but 
also included plasma cells and occasional polymorphonuclear 
leukocytes. Diffuse edema of the myocardium was also found. 
The focal inflammatory lesions were most numerous in the 
inner two-thirds of the myocardium and most often appeared 
around small vessels. They were also found in the rest of 
the heart but in fewer numbers. Of the eleven patients who 
did not have active myocarditis, eight exhibited patchy 
myocardial fibrosis. Two showed marked myocardial fibrosis 
similar in appearance and distribution to the fibrosis of 
those with active myocarditis. This pattern was remarkably 
similar to that found in rats. All of the animals that died 
or were killed within five days of the initial injection of 
norepinephrine had active myocarditis. Fifteen of twenty- 
seven rats killed after three, four, and eight weeks showed 
increased amounts of fibrous tissue which was present focal- 
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ly around vessels, primarily in the inner two-thirds of the 
left ventricular myocardium. 
Stress is another example in which there is excess 
endogenous catecholamines. It is well established that all 
types of stress, e.g., physical, emotional, or sensory, 
result in increased plasma catecholamines concentration 
secondary to sympathetic activation (28). The major early 
experimental studies of Selye showed that various types of 
stress such as prolonged restraint, caloric, surgical, and 
bacteriotoxic stress, vagotomy, and injection of norepineph¬ 
rine or epinephrine elicited the same type of cardiac necro¬ 
sis in rats that had been preconditioned with corticoste¬ 
roids (29) . 
Raab was one of the major investigators in stress- 
induced cardiomyopathy. In 1961, he confirmed Selye's ob¬ 
servations that cardiac necroses occurred in rats pretreated 
with fluorocortisol and exposed to prolonged restraint, cold 
stress, or nicotine (known to release catecholamines), with 
the latter two being less effective in producing lesions 
(28). He also found that various antiadrenergic agents such 
as reserpine (catecholamine depleting), dibenamine (adrener¬ 
gic blocking), mecamylamine (ganglionic blocking), and 
chlorpromazine (centrally inhibiting), protected the heart 
muscle of rats preconditioned with corticosteroids from 
stress-induced cardiac necroses. Since all stressful situa¬ 
tions are accompanied by a reflex discharge of adreno- 
sympathogenic catecholamines, Raab postulated that the ex¬ 
cess amount of endogenous catecholamines was a common media- 
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tor in the pathogenesis of stress-induced myocardial lesions 
in animals preconditioned with corticosteroids. 
In a 1963 review of the literature concerning catechol¬ 
amines and myocardial necroses, Raab (30) cited studies 
which supported his theory. He noted that accumulation of 
catecholamines in heart muscle itself has been observed 
under direct stimulation of cardiac sympathetic nerves, 
stimulation of the midbrain, and under various catecholamine 
liberating stresses such as enforced exercise, cold expo¬ 
sure, insulin overdosage, or restraint. Also, direct elec¬ 
trical stimulation of the sympathetic nerves supplying the 
heart for several hours results in subendocardial hemor¬ 
rhages and necroses similar to those elicited by prolonged 
infusion of norepinephrine. 
Later animal studies showed that stress can induce 
myocardial lesions even in the absence of hormonal pretreat¬ 
ment. In 1964, Raab reported finding myocardial necrosis 
in 69% of wild rats exposed to frightening noises following 
periods of isolation (31). In contrast, myocardial lesions 
were elicited by emotional stress in only one-third to one- 
half of nonisolated, domesticated white rats even after 
pretreatment with corticosteroids. 
The cardiovascular system of the pig is considered to 
be more comparable to that of man than of other animals 
mainly used for cardiovascular research such as rats or dogs 
(32,33). Johansson et al (34) found that "restraint 
stress," i.e., prevention of escape behavior by injection of 
a myorelaxant while administering painful electric shocks, 
produced a severe cardiopathy which resulted in sudden death 
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in 13% of the animals. Subendocardial hemorrhages with 
fragmentation, granulation, and necrosis of the heart muscle 
cells, proliferation of histiocytes and fibroblasts, and 
slight polymorphonuclear infiltration developed within 24 to 
48 hours. The authors noted the similarity of the lesions 
to those induced by catecholamines. 
Cardiomyopathy could also be produced in pigs by the 
physical stress of high sustained positive G force as des¬ 
cribed by Mackenzie et al (35) in 1976. Examination of the 
stressed pig hearts showed myofibrillar degeneration, pool¬ 
ing of mitochondria, and cell death. Lesions occurred in 
random cells of the subendocardium and papillary muscles. 
Meerson (36) describes another experimental model in 
which emotional and painful stresses are induced as a rat 
waits intensely for painful electric shocks which it re¬ 
ceives at occasional intervals. Morphologically, he found 
complete contracture of the myocardial cells within 39 to 45 
hours. This was followed by muscle cell death with degener¬ 
ation and formation of fibroblastic ’’granulomas” in some 
cases, and the appearance of a cellular infiltrate around 
necrotic muscle fibers. 
Thus, stress cardiomyopathy has been described in the 
literature characterized by focal myocardial necrosis or 
myofibrillar degeneration. Specifically, the cardiac lesion 
in stressed animal experiments consists of scattered indivi¬ 
dual or small clusters of myocytes showing homogeneous eo¬ 
sinophilic transverse bands alternating with areas of fine 
granulation. This pattern has been termed myofibrillar 
. 
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degeneration (37). While the studies cited above support 
the theory that stressful sensory and emotional stimuli 
might produce cardiomyopathy in laboratory animals, direct 
evidence in man is harder to obtain. Cebelin and Hirsch 
(38) in 1980 did a retrospective review of autopsy findings 
of homicide victims over 30 years in Cuyahoga County, Ohio 
and identified fifteen victims who died as a result of 
direct physical assault without sustaining internal inju¬ 
ries. Eleven showed cardiac changes (myofibrillar degener¬ 
ation) consistent with the "stress cardiomyopathy" that had 
been described in animal experiments. The authors inter¬ 
preted the data as being strongly supportive of the theory 
of catecholamine mediation of these myocardial changes in 
man and of the lethal potential of stress through its ef¬ 
fects on the heart. 
While the damaging properties of catecholamines have 
been extensively studied, the mechanism by which they result 
in myocardial injury is not well understood. One of the 
prominent theories postulates that high concentrations of 
catecholamines result in myocardial calcium overload with 
subsequent hypercontraction and myofibrillar necrosis (39). 
If this is correct, it seems reasonable to assume that 
administration of a drug which prevents entry of calcium 
into myocytes, such as one of the calcium channel blockers, 
should result in reduction of the injury. Calcium channel 
blockers are known to act as specific inhibitors of the slow 
transsarcolemmal calcium influx but do not (or only slight¬ 
ly) affect the fast sodium current that initiates normal 
myocardial excitation. In fact, Fleckenstein (40) has done 
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experiments in which he found that the calcium channel 
blocker, verapamil, reduces isoproterenol-induced myocardial 
necrosis. However, there have been few studies investigat¬ 
ing the effects of calcium channel blockers on the natural¬ 
ly-occurring catecholamines, epinephrine and norepinephrine. 
In this thesis, the possible protective effects of verapamil 




The pathology of catecholamine-induced cardiomyopathy 
has been well characterized. Before the lesion is de¬ 
scribed, the normal myocardial ultrastructure will be re¬ 
viewed. Components of normal myocardium include: 1) cardiac 
muscle cells, 2) vascular elements - arterial, venous, and 
lymphatic vessels, and capillary network, 3) connective 
tissue cells - pericytes, fibroblasts, mast cells, primitive 
mesenchymal cells, and histiocytes, 4)neural elements, and 
5) extracelluar elements of connective tissue such as colla¬ 
gen fibers, elastic fibers, and connective tissue microfi¬ 
brils and proteoglycans. Within the cardiac muscle cells, 
sarcomeres form the functional units of contraction. Sarco¬ 
meres are attached end to end and packaged in myofibrils 
which are arranged parallel to the longitudinal axis of the 
cell. Alignment of the sarcomeres is responsible for the 
striated appearance of the myofibrils (Z-lines). Sarcomeres 
consist of A bands which contain myosin in the form of 
"thick” filaments, I bands containing actin in the form of 
"thin" filaments, and Z bands which contain alpha-actinin 
and other incompletely characterized proteins. The thick 
and thin filaments interdigitate so that each thick filament 
is surrounded by six thin filaments. The interaction of the 
thick and thin filaments constitutes the basis for the 
sliding filament mechanism of muscle contraction (41). 
Catecholamine-induced lesions are characterized by a 
particular form of cardiac cell necrosis termed myofibrillar 
degeneration by Reichenbach and Benditt (37). This consists 
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of clumping and disorganization of the cardiac myofibrils 
followed by degenerative changes in cell cytoplasm and min¬ 
eralization of mitochondria. The lesions are similar in all 
species (including man) and show little variation with the 
catecholamines used or route of administration (1). The 
nature of the lesion is determined by the amount of time 
that has elapsed between the administration of the drug and 
sacrifice of the animal. Severity and extent of the lesion 
varies directly with dose and rate of administration. 
On gross examination, focal and diffuse subendocardial 
hemorrhages are seen shortly after exposure to catechola¬ 
mines which are especially prominent in the left ventricle 
and papillary muscles (7,6,13,15,16). Myocardial hemor¬ 
rhages are also seen (13). The subendocardial and myocar¬ 
dial hemorrhages occur in both ventricles, right atrium, 
right atrial wall, and in the mitral valve (13). Hemorrhage 
has also been observed in the pericardium and subepicardium 
(13). Within 48 hours, the lesions appear as well demar¬ 
cated pale greyish-yellow areas involving the apical area of 
the heart (17,25). The tricuspid, mitral, and aortic valves 
become edematous and distorted with occasional hemorrhages 
noted on the valves (6,7). Within 4 to 5 days fibrosis 
begins and progresses (15,27), resulting in indistinct lin¬ 
ear scars or chronic aneurysm formation (20). 
By light microscopy, the immediate findings after 
exposure to catecholamines are interstitial edema, subendo¬ 
cardial congestion and hemorrhages, especially adjacent to 
Thesbian vessels (15). Myofibrillar degeneration with ne¬ 
crosis of the fibers can be demonstrated as early as 2 to 3 
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minutes after a single intravenous injection of isoprotere¬ 
nol (37). By 6 to 10 hours an inflammatory response becomes 
evident consisting of an intense interstitial leukocytic 
reaction most pronounced in subendocardial and midzonal 
portions of the left ventricle but occasionally extending to 
the subepicardial region (9,10,15,16,19), and uniformly 
involving the papillary muscles (42). The cellular infil¬ 
trate is predominantly mononuclear cells in which large 
histiocytic cells are most numerous (15,42,43,27). The peak 
of myocardial necrosis is reached by 48 hours (19,20) with 
complete destruction of muscle fibers evident and a full 
blown interstitial mononuclear cell reaction. Though car¬ 
diac histiocytes are most numerous and tended to concentrate 
in association with foci of myofiber necrosis (15,42,43), 
they were occasionally accompanied by lymphocytes, granulo¬ 
cytes (10,15,42,43), and perivascular Anitschkoff myocytes 
(26,44). 
In addition to fragmentation and local myofiber de¬ 
struction, numerous contraction bands are also seen in the 
myocardium (22,43). These represent irregular, acidophilic 
coagulation or condensations of contractile proteins forming 
transverse bands, and numerous hypercontracted sarcomeres. 
Also present are zones of granularity consistent with swol¬ 
len mitochndria (24,43). 
By 72 hours thin bands of connective tissue which 
stained as collagen become evident (15,26) and the necrotic 
muscle fibers are partly replaced by fibroblasts (19). Ear¬ 
ly manifestations of healing with proliferation of fibro- 
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blasts at the margins of necrotic areas are present by 4 to 
5 days (9,24,25). In 5 to 6 days, the necrotic muscle 
fibers have been resorbed and the interstitial reaction 
becomes prominent with numerous Anitschkow cells seen among 
the proliferating fibroblasts (17). The involved areas 
consist of sheets of histiocytes and fibroblasts suggesting 
a granulomatous pattern which peaks in 5 to 7 days (19,20). 
By 1 week, there is evidence of continuing phagocytosis of 
necrotic fibers and healing by fibrosis (15,37). At 2 
weeks, only fibrous areas are present (15,27). The "granu¬ 
lomatous” areas are eventually replaced by fibrous tissue 
(44), ultimately leading to indistinct linear scars or 
chronic aneurysm formation (20). 
No lesions have been observed in the larger coronary 
arteries or myocardial arterioles (9,16,43). Occasionally, 
thrombi are seen in intramural coronary arteries (6,16), but 
in other studies these have been absent (43). Branches of 
the coronary arteries and arterioles occasionally show fi¬ 
brinoid degeneration, even in areas where necrosis of the 
myocardium is not apparent (44). 
Accumulation of lipid droplets within isolated or 
groups of cardiac cells may also be found. This is seen 
immediately after exposure to catecholamines (7,10,14,15). 
Fatty degeneration of the myocardium has been reported 
(7,16). 
U1trastructural changes involve the myofibrils, sarco¬ 
plasmic reticulum, mitochondria, and lysosomes. Cells show 
a loss of glycogen and accumulation of neutral lipid. 
Changes in the myofibrils evidenced by marked thickening of 
_ 
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the Z lines have been noted as early as 30 minutes following 
exposure to catecholamines (10), consistent with hypercon¬ 
traction of sarcomeres. There is loss of the orderly ar¬ 
rangement of myofilaments as myofibrillar degeneration pro¬ 
gresses (24,25). By 6 to 12 hours, the Z line becomes less 
osmiophilic, and less distinct as the inflammatory response 
appears (10,37,43). 
The ordinarily flattened vesicles of the sarcoplasmic 
reticulum become swollen (10,37), and lipid droplets can be 
seen in the sarcoplasm. The mitochondria exhibit marked 
swelling and loss of cristae. Necrotic cells have the most 
severely damaged mitochondria (10,16,24,25,37). Osmiophilic 
inclusions within the mitochondria also appear and probably 
represent calcium accumulation granules (16,24,37,45). 
An increased number of lysosomes in cardiac muscle 
cells can be seen throughout the myocardium, but these are 
especially prominent in cells adjoining the necrotic areas 
(10). 
In summary, the main characteristics of the catechola¬ 
mine-induced mycardial lesion are myofibrillar degeneration, 
contraction bands, and interstitial mononuclear infiltrate 
composed primarily of histiocytes, with most of the damage 
occurring in the subendocardial regions. The acute injury 




Despite the well characterized pathology of catechola¬ 
mine-induced cardiomyopathy, the exact mechanism by which 
catecholamines produce myocardial lesions is uncertain. 
Numerous theories have been advanced and these may be 
grouped into two broad categories. The first invokes isch¬ 
emia or relative hypoxia as the cause of the lesions, and 
the second presumes that catecholamines have a direct toxic 
effect on the myocardium leading to membrane permeability 
alterations. 
Many of the early investigators favored ischemia as a 
major factor in catecholamine-induced cardiomyopathy (21). 
Raab (30) theorized that adrenergic amines in excessive 
amounts, whether produced endogenously (as in severe stress 
or pheochromocytoma) or administered exogenously can elicit 
disproportions between supply and demand for oxygen in the 
myocardium causing myocardial necrosis. He concluded that 
the subendocardial location of catecholamine-induced necro¬ 
ses could be explained by the increased susceptibility of 
the ventricular inner layers to anoxia secondary to vascular 
compression when the intraventricular pressure rises. The 
cardiotoxic ity of catecholamines is abetted by a reduction 
or absence of compensatory coronary dilatation. Based on 
experimental findings which showed that: 1) increased endo¬ 
genous or exogenous catecholamines levels in the heart are 
associated with potassium depletion, 2) loss of myocardial 
potassium is secondary to hypoxia, and 3) dietary potassium 
deficiency results in focal necrotic lesions in the myocar- 
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dium, Raab proposed the following hypothesis: 
"Exaggerated catecholamine action (either due to 
exogenous administration or to intrinsic libera¬ 
tion) is capable of causing anoxia in vascularly 
handicapped, and therefore, particularly vulnera¬ 
ble myocardial cell groups. A resulting altera¬ 
tion of cell membrane permeability permits the 
escape of potassium from the anoxic cell groups 
and this disturbance in local electrolyte distri¬ 
bution initiates the process of multifocal cell 
destruction (30)." 
In view of findings which showed that adrenal corticoid 
pretreatment markedly aggravated catecholamine-induced car¬ 
diomyopathy, Raab further postulated that exaggerated stimu¬ 
lation of the catecholamine-liberating adrenosympathetic 
system accompanied by adrenocorticoid overactivation is the 
common, potentially cardiotoxic denominator of all forms of 
acute stress, and primarily responsible for all stress- 
induced cardiac lesions (30). 
Rona (8), in his early studies of isoproterenol necro¬ 
sis, was a proponent of the ischemic theory of catechola¬ 
mine-induced cardiomyopathy. However, he now feels that a 
direct toxic effect is the major factor but that alterations 
in the coronary microcirculation contribute to the necrosis 
as well. In an early paper comparing the cardiotoxic ac¬ 
tions of isoproterenol, epinephrine, and norepinephrine, 
Rona (8) stated that epinephrine was believed to cause 
myocardial lesions due to its cardiac stimulating proper¬ 
ties, thus increasing the oxygen requirements of the myocar¬ 
dium so that despite coronary vasodilation, a relative in¬ 
sufficiency of oxygen was produced. Therefore, since the 
study showed that isoproterenol was a more potent cardiac 
stimulator than the other two catecholamines, it would also 
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be expected to cause myocardial necrosis by increasing myo¬ 
cardial oxygen requirements and decreasing systemic blood 
pressure. Handforth (18) also considered isoproterenol 
necrosis to be ischemic in nature. He injected India ink 
into the coronary arteries of hamsters sacrificed shortly 
after injections of isoproterenol and demonstrated that 
blood flow to the subendocardium of the left ventricular 
wall was markedly reduced, even prior to the development of 
myocardial edema or necrosis. The areas affected by isch¬ 
emia proved to be the sites at which necrosis subsequently 
developed. Thus, he felt that isoproterenol-induced lesions 
were infarcts secondary to local myocardial ischemia and 
suggested that the ischemia may be due to either vasocon¬ 
striction or vascular shunts allowing blood to bypass capil¬ 
lary vessels. 
Ferrans et al (46) studied isoproterenol-induced myo¬ 
cardial necrosis and found thickened and increased density 
of Z bands, swelling of mitochondria, and enlargement of the 
vesicles of the endoplasmic reticulum within the first cou¬ 
ple hours of isoproterenol administration. This was followed 
by myofibrillar degeneration and lipid droplet accumulation 
in the spaces between myofibrils as well as in the endoplas¬ 
mic reticulum. These findings as well as the subendocardial 
distribution of the lesions were attributed to the exagger¬ 
ated demand for oxygen imposed on the coronary circulation 
by catecholamine-induced stimulation of myocardial metabo¬ 
lism. These findings support the concept that hypoxia plays 




Lehr et al (47,48) have recently presented experimental 
findings supporting their theory of catecholamine-induced 
cardiomyopathy. They concluded that the electrolyte derang¬ 
ing and necrosis-inducing properties of catecholamines are 
primarily due to a discrepancy between coronary vascular 
adaptability of flow and the greatly augmented oxygen de¬ 
mand. This results from either the positive inotropic and 
pronounced hypotensive effect of the beta adrenergic ag¬ 
onists, or the pronounced increase in peripheral resistance 
and constriction of the coronary vasculature caused by alpha 
adrenergic agents. Ischemia may be the ultimate common 
pathway in the mechanism of myocardial injury elicited by 
all adrenergic amines, since an identical pattern of isch¬ 
emic cationic abnormalities was found to occur in the myo¬ 
cardium of both alpha and beta adrenergic amine-induced 
injury. This pattern starts with a fall in myocardial 
magnesium concentration, followed by a rise of calcium and 
sodium, and in severe injury, a reduction in potassium (48). 
Lehr has concluded that it is ischemia rather than 
calcium overloading, as proposed by many other investigators 
that represents the primary mechanism of myocardial injury. 
Thus cardiac hypoxia is the main cause of the myocardial 
electrolyte disturbances which, in turn, may contribute to 
the initiation of a state of irreversible failure of cellu¬ 
lar function. In particular, Lehr emphasized the role of 
magnesium loss. Myocardial necrosis involves an early ob¬ 
ligatory loss of intracellular magnesium, which precedes the 




Lehr’s (48) studies of coronary artery ligation in the 
rat demonstrated the occurrence of early magnesium loss. 
The first significant changes in the myocardial bulk elec¬ 
trolyte content were apparent thirty minutes after ligation 
and consisted of depletion of magnesium, potassium, and 
phosphate. Significantly, calcium content was normal at 
that time. One hour after coronary artery occlusion, the 
first moderate rise in calcium content coincided with highly 
significant alterations of the other five electrolytes. 
Similar observations were made with myocardial injury pro¬ 
duced by either alpha or beta adrenergic amines. One hour 
after injection of a necrotizing dose of either isopro¬ 
terenol (beta agonist), phenylephrine (alpha agonist), or 
epinephrine (alpha and beta agonist), i.e., at a point in 
time when structural injury is as yet not readily demonstra¬ 
ble, significant loss of magnesium is uniformly present as 
the sole electrolyte disturbance. The calcium concentration 
begins to rise only subsequently, and is shown to have 
reached significantly increased levels at the three hour 
interval when necrosis is clearly apparent. 
Further support for a contributory role of electrolyte 
shifts in the mechanism of cellular injury can be derived 
from studies indicating that administration of electrolyte 
solutions containing either magnesium or potassium salts 
results in protection against catecholamine-induced necro¬ 
sis. 
Lehr’s view of the secondary nature of calcium over¬ 
loading is supported by his studies with parathyroidecto- 
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mized rats (48). Such animals failed to show any noticeable 
degree of protection against catecholamine-induced myocar¬ 
dial necrosis despite complete prevention or highly signifi¬ 
cant inhibition of myocardial calcium accumulation. In 
addition, Lehr's group was able to confirm Fleckenstein's 
(40) observation of the propranolol-1ike protective effect 
of verapamil in isproterenol-induced myocardial necrosis. 
However, cardiac injury elicited by phenylephrine was like¬ 
wise inhibited by verapamil but not by propranolol. Also, 
verapamil was equally protective in parathyroidectomized 
rats against isoproterenol-induced necrosis (that is, in the 
absence of myocardial calcium accumulation). Therefore, Lehr 
concluded that the beneficial effect of verapamil must be 
based on a property other than its calcium channel blocking 
capabilities and might be due instead to its negative ino¬ 
tropic, and thus oxygen sparing effects. 
In line with the ischemic theory, Haft et al (49-51) 
has proposed that intracoronary platelet aggregation may 
contribute to the mechanism that leads to myocardial isch¬ 
emia in catecholamine-induced cardiac necrosis. In view of 
the well known antiaggregating effects of aspirin and di¬ 
pyridamole on platelets, Haft (50) pretreated ten dogs with 
aspirin and ten dogs with dipyridamole followed by infusion 
with epinephrine at 4 ug/kg/min for four hours. He found 
that only three animals in each group exhibited any myocar¬ 
dial necrosis whereas all animals in the nonpretreated con¬ 
trol group exhibited significant myocardial necrosis. Fur¬ 
thermore, they were able to demonstrate platelet aggregates 
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within the small vessels of the hearts of dogs infused with 
norepinephrine (50) and in rats given isoproterenol (51). 
Other investigators, however, have been unable to confirm 
the finding of platelet aggregates in coronary vessels 
(27,42,43). 
Hoak (16) found that following norepinephrine infusions 
in dogs only a few of the small myocardial vessels were 
noted to be occluded by platelet aggregates. However, these 
were not seen often enough to represent the sole cause of 
the myocardial necrosis and in no instance were coronary 
arteries found to be occluded. Therefore, it does not 
appear that platelet aggregation is a major factor in cate- 
cholmine-induced myocardial necrosis. 
Several studies are inconsistent with the ischemia 
hypothesis. Ostadel et al (52) found that isoproterenol 
induces myocardial necrosis in the turtle. This is signifi¬ 
cant because the turtle does not have coronary arteries, but 
relies on the blood in the ventricular chambers to sustain 
the myocardium. These findings do not support Lehr’s hypo¬ 
thesis that myocardial necrosis is precipitated by isopro¬ 
terenol-induced decreased peripheral vascular resistance, 
decreased systemic blood pressure, and hence lower coronary 
blood flow resulting in ischemic cardiac injury. Ostadel’s 
study does not rule out the possibility, however, that 
catecholamines increase the demand for oxygen so much that 
demand outstrips supply and causes relative anoxia. 
Downing’s (42,43) studies of norepinephrine-induced 
cardiomyopathy in rabbits indicate that a supply-demand 
mismatch causing ischemic injury to the myocardium is un- 
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likely. He found that although mean arterial blood pressure 
rose, the heart rate fell, and calculations of the pressure- 
rate product suggested no increase in myocardial oxygen 
consumption throughout the course of norepinephrine infu¬ 
sion. Also, the histological pattern and leukocytic re¬ 
sponse differed from that expected with myofiber necrosis 
following an ischemic insult. An ischemic insult results in 
a predominantly polymorphonuclear infiltrate. However, in 
catecholamine-induced cardiomyopathy, the infiltrate con¬ 
sists primarily of histiocytic mononuclear cells. Morever, 
ischemia in which coronary flow does not remain interrupted 
frequently is accompanied by capillary damage and intersti¬ 
tial hemorrhage. These were never observed in Downing’s 
studies nor was coronary vascular injury or thrombus forma¬ 
tion identified by light microscopy. 
The second category of theories concerning pathogenesis 
of catecholamine-induced cardiomyopathy postulate that cate¬ 
cholamines have a direct cardiotoxic effect. The calcium 
overload concept of Fleckenstein is a major theory in this 
group. Isoproterenol-induced excessive calcium influx into 
the myocardial cell is thought to cause injury and necrosis 
by exaggerated activation of calcium-dependent ATPases and 
the consequent exhaustion of ATP and creatine phosphate 
reserves (39). For a better understanding of this theory, 
the normal mechanism of catecholamine action and salient 
features of myocardial energy metabolism will be presented. 
Durret and Adams (53) recently reviewed the mechanisms 
by which catecholamines exert their effects. These agents 
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interact with beta-1 adrenergic receptors on the extracellu¬ 
lar surface of the sarcolemma to elicit their positive 
inotropic and chronotropic effects on the heart. The mech¬ 
anism responsible for the positive inotropic effect appears 
to be enhancement of the slow inward calcium current and 
increased intracellular calcium concentration. Activation 
of the beta receptor stimulates the enzyme adenylate cy¬ 
clase, resulting in an increase in the intracellular concen¬ 
tration of cAMP. The exact mechanisms by which cAMP leads 
to increased contractility are not known. It is established 
that cAMP-dependent protein kinases phosphorylate proteins 
associated with myofibrils, the sarcoplasmic reticulum, and 
the sarcolemma. It may therefore affect contractility via 
several cellular mechanisms: 1)cAMP may act directly on the 
myofibrils by phosphorylation of myofibril components, F 
actin and troponin; 2)cAMP may increase calcium availability 
by enhancing calcium uptake by the sarcoplasmic reticulum; 
or 3)cAMP may also modulate calcium entry into the myocar¬ 
dial cell by inducing the phosphorylation of a specific 
protein in the sarcolemma by protein kinase, thereby, open¬ 
ing up membrane "channels" to allow the influx of calcium. 
The result is that the increase in calcium concentration 
inactivates the troponin-tropomyosin system and permits 
enhanced interaction of the actin and myosin filaments. 
Bloom (54) noted that a special feature of myocardial 
energy metabolism is the existence of a large amount of 
creatine phosphate (CP), the alternative storage form to ATP 
for high energy phosphate. CP is also important to the 
myocardium as it serves to buffer the ATP concentrations, 
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i.e., as ATP is converted to ADP through normal metabolic 
processes such as contraction, the ATP can be resynthesized 
either by electron-transport related processes, or at the 
expense of creatine phosphate through the action of creatine 
phosphokinase. Thus, a fundamental function of oxidation 
and glycolysis consists of maintaining a sufficiently high 
level of ATP and CP in the myocardial fiber for two impor¬ 
tant functions. The first is to supply energy for contrac¬ 
tion and to d-rive the "ion pumps" (active transport of 
sodium, potassium, and calcium ions connected with bioelec¬ 
tric and mechanical performance). And the second is to meet 
the energy expenditure for various synthetic reactions that 
are necessary for continuous cellular repair. 
According to Fleckenstein (39,40,55,56), severe myocar¬ 
dial cell damage, as well as contractile failure, will occur 
when the high-energy phosphate stores are exhausted, as in 
excessive ATP consumption by the heart due to beta adrener¬ 
gic stimulated mechanical hyperactivity. Physiologically, 
catecholamines increase myocardial tension by enhancing the 
utilization of high energy phosphates for contraction. 
Overdoses of catecholamines, however, stimulate the split¬ 
ting of ATP in the contractile machinery so excessively that 
not enough ATP is left for the various synthetic processes 
which are involved in regeneration of the living structures. 
Fleckenstein was able to demonstrate that high energy phos¬ 
phate becomes critical when the ATP concentration in myocar¬ 
dium is lowered by more than 50% and the corresponding CP 
concentration falls by more than 80% (40). He showed that 
1 
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injections of isoproterenol into rats caused reductions in 
ATP and CP below the critical levels and this was associated 
with myocardial fiber necrosis (40). 
In a series of studies, Fleckenstein et al 
(39,40,55,56) showed that the cardiotoxic effects of beta 
adrenergic catecholamines, including isoproterenol, are 
mediated by calcium ions, and that these ions play a key 
role in the production of cardiac necroses. After isopro¬ 
terenol administration to rats, there is an increased move¬ 
ment of 45£a2+ from plasma into heart muscle, and the myo¬ 
cardial content of calcium can be observed to increase. In 
addition, the ATP content was found to fall. These workers 
also demonstrated that calcium ions are highly cardiotoxic 
if they are taken up excessively into the myocardial fibers; 
and that intracellular calcium overload initiates a break¬ 
down of ATP and CP. Morever, calcium-induced high energy 
phosphate exhaustion is crucial in the etiology of myocar¬ 
dial fiber necroses produced by a number of cardiotoxic 
agents, including large doses of beta adrenergic catechol¬ 
amines, vitamin D, dihydrotachysterol, cardiac glycosides, 
etc., or conditions of extreme physical or emotional stress. 
The mechanism by which calcium overload leads to myo¬ 
cardial necrosis is somewhat complex. Catecholamines in¬ 
crease transmembrane calcium influx into the excited myocar¬ 
dial fibers. This leads to activation of the calcium depen¬ 
dent myofibrillar ATPase that transforms phosphate-bond 
energy into mechanical work as well as the calcium transport 
ATPases of the sarcoplasmic reticulum and mitochondria. 
With increasing doses of these drugs, continued calcium 
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uptake and excessive splitting of ATP and CP occurs. In 
addition, the increase in intracellular calcium leads to 
structural damage and calcification of the mitochondria, im¬ 
pairing their phosphorylating capacity. Active extrusion of 
calcium from the calcium-overloaded myocytes occurs as long 
as ATP is availabe for this purpose. But in the advanced 
stages of ATP deficiency, the calcium extrusion seems to 
decline rather rapidly, so that a steep rise of the intra¬ 
cellular calcium concentration occurs. The calcium overload 
initiates a breakdown of ATP and CP, with the result that 
cardiac function and structural integrity cannot be main¬ 
tained . 
The intracellular sites where myocardial calcium over¬ 
load induces exhaustive ATP consumption include the myofi¬ 
brils, sarcoplasmic reticulum, and mitochondria. The first 
reaction of the contractile system to excessive splitting of 
ATP by the calcium activated myofibrillar ATPase consists of 
a supercontraction. Abundant transsarcolemmal calcium in¬ 
flux produces a state of excitation-contraction "overcou¬ 
pling” by which the myofilaments are eventually destroyed if 
the myocardial fiber cannot reduce the calcium overload in 
time. Apart from myofibrillar destruction, intracellular 
calcium overload is most injurious to the mitochondria. 
This is signaled by the appearance of intramitochondrial 
calcium phosphate precipitates. Fleckenstein (56) found that 
cardiac mitochondria in situ incorporate large amounts of 
calcium when overdoses of isoproterenol are administrated. 
Mitochondrial swelling, vacuolization, and cristolysis occur 
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probably as a self-defense mechanism (calcium-buffer) 
against a disproportionate rise in the cytoplasmic free 
calcium concentration that exaggerates ATP consumption. 
When, however, necrotizing doses of isoproterenol are admin¬ 
istered, transsarcolemmal calcium inflow is so dramatically 
stimulated that there is a toxic accumulation of calcium. 
Rona et al (57-60) have incorporated Fleckenstein's 
calcium overload concept into their own theory. While re¬ 
taining the importance of coronary microcirculatory factors 
in the evolution of catecholamine-induced cardiomyopathy, 
the early sarcolemmal membrane permeability alterations 
demonstrated by their studies with horse radish peroxidase 
(HRP), suggest a direct toxic effect of catecholamines. In 
their studies, isoproterenol, norepinephrine, and epineph¬ 
rine were administered to rats followed by injection of 
HRP. In control rats given HRP, the tracer became uniformly 
distributed in the myocardial interstitium and transverse 
tubular system with pinocytotic vesicles noted at the border 
of the sarcolemma of myocytes. However, the sarcolemma was 
never penetrated by the tracer. With norepinephrine and 
epinephrine infusion, HRP reached the interstitium more 
rapidly than in the controls and also appeared within some 
myocytes as early as ten minutes after infusion in the case 
of norepinephrine. Significantly, many of the cells con¬ 
taining HRP were ultrastructurally normal. Infusion of 
isoproterenol produced similar findings except they occurred 
after the isoproterenol-induced drop in blood pressure had 
returned to normal. The subsequent appearance of the tracer 
in the myocardial interstitium was followed by its presence 

28 
in some of the myocytes. 
Rona attributed these differences in the temporal 
course of the appearance of HRP to the varying pressor and 
depressor properties of the catecholamines and their subse¬ 
quent effect on the coronary microcirculation. Although 
norepinephrine and epinephrine constrict large coronary 
vessels, they dilate small coronary branches. When coupled 
with their pressor effect on systemic blood pressure, coro¬ 
nary blood flow is improved, thus accounting for the early 
interstitial appearance of HRP. In contrast, isoproterenol, 
through its vasodilating effects on the peripheral vascula¬ 
ture, causes an initial, transient hypotension which offsets 
the coronary vasodilation produced both directly and indi¬ 
rectly by increased metabolic demand and thus results in the 
delay in appearance of HRP. 
Following infusion of all three catecholamines, one of 
the earliest changes noted was the passage of HRP across the 
sarcolemma of normal appearing cells to be deposited on 
myofibrils. This suggested that some form of injury result¬ 
ing in early permeability had occurred. In addition, HRP 
showed a marked affinity for hypercontracted or necrotic 
myofilaments in structurally damaged cells. A later finding 
is HRP deposition along mitochondrial cristae indicating 
that the mitochondrial membrane had become permeable to the 
macromolecular tracer. 
In several recent papers, Rona et al (59,60) have noted 
the similarity between reperfusion injury and catecholamine- 
induced injury, particularly that which follows isoprotere- 
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nol administration. They both exhibit contraction band for¬ 
mation and mitochondrial calcium phosphate deposits. Fur¬ 
thermore, permeability alterations of myocardial cells in 
reperfusion injury parallel those seen in catecholamine- 
induced injury. Cardiac cells made ischemic by coronary 
artery ligation for ten minutes followed by reperfusion for 
sixty minutes were structurally normal except for abundant 
lipid droplets. Sixty minutes of ischemia followed by reper¬ 
fusion induced HRP deposition resembling that found with 
isoproterenol infusion in which there was contraction band 
necrosis with heavy deposition of HRP on hypercontracted 
myofilaments. These findings suggest a common causal path¬ 
way consisting of microcirculatory derangement plus direct 
cardiac muscle cell stimulation, possibly mediated by the 
release of catecholamines. Thus, Rona concluded that the 
pathogenesis of catecholamine-induced lesions involves rela¬ 
tive hypoxia, altered membrane permeability, and primary 
myofilament stimulation. These act together to produce 
calcium overload which activates calcium dependent myofi¬ 
brillar ATPase. Depletion of ATP and CP levels results in 
myofilament hypercontraction and loss of structural integ¬ 
rity as described by Fleckenstein. 
Other mechanisms which have been suggested include 
increased serum free fatty acid (FFA) levels in view of the 
lipid deposits observed in hearts following administration 
of catecholamines (7,14). Hoak (16) found elevated serum 
FFA in dogs following infusions of norepinephrine. He theo¬ 
rized that the stimulatory effect of catecholamines on lipid 
metabolism plays an important part in the production of 
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cardiac lesions. With the mobilization of lipid from adi¬ 
pose tissue induced by catecholamines, the plasma level of 
FFA increases and may lead to their accumulation within the 
myocardial cell. Accumulation of long chain fatty acids can 
cause uncoupling of oxidative phosphorylation and direct 
tissue damage. However, catecholamine infusions in rabbits 
do not cause a concomitant increase in FFA unlike the dog or 
rat (15). In this species a mechanism of injury that does 
not involve an increase in plasma FFA must be present . 
Oxidation of FFA by the myocardial cell may certainly be 
inhibited during catecholamine injury resulting in cellular 
overload with fatty acids. 
Mallov (61) also concluded that FFA are involved in the 
production of myocardial necrosis by catecholamines. Cate¬ 
cholamines increase FFA levels by stimulating lipolysis in 
depot fat. He suggested that high concentrations of cate¬ 
cholamines cause increased influx of calcium and FFA into 
myocardial cells, and that these are deposited as soaps. 
Soaps may produce alterations in plasma membrane permeabili¬ 
ty, permitting increased rates of influx and deposition to 
continue, ultimately causing cell damage and death. 
Other investigators have concentrated on the direct 
cardiotoxic effects of catecholamine metabolites. Yates et 
al (62) proposed that oxidation products of catecholamines 
such as adrenochrome, rather than catecholamines per se, may 
play a role in the pathogenesis of catecholamine injury by 
causing cell necrosis and contractile failure. This was 
based on studies (62-64) in which perfusion of isolated rat 
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hearts with fresh isoproterenol or epinephrine failed to 
induce necrosis in the myocardium. But lesions were found 
in hearts that had been perfused with isoproterenol that had 
undergone spontaneous oxidation in solution. Furthermore, 
perfusion of rat hearts with adrenochrome produced similar 
lesions along with of contractile failure. The hemodynamic 
effects of catecholamines, including reduced endocardial 
perfusion resulting from lower diastolic blood pressure, 
shortened diastole, and/or coronary vascular changes, were 
thought to cause stagnation of blood flow and allow accumu¬ 
lation of catecholamine oxidation products. These factors, 
by potentiating the deleterious effects of catecholamine 
oxidation products on oxidative phosphorylation and glucose 
metabolism, could also produce relative hypoxia. Thus, they 
concluded that catecholamine-induced lesions resulted from 
the combined effects of catecholamines and their oxidation 
products, including the adrenochromes. 
Free-radicals are produced during autoxidation of cate¬ 
cholamines, and Singal et al (25) suggested that catechol¬ 
amine-induced changes in the heart may also involve an 
increase in free-radical activity. They found that pre¬ 
treatment of rats with either vitamin E or zinc prevented 
isoproterenol injury. Since vitamin E is an antioxidant, it 
could act as a free-radical scavenger to prevent the cell 
membrane damaging effects of free radicals. Cell membranes 
contain high concentrations of highly unsaturated fatty 
acids and thus are susceptible to free-radical induced lipid 
peroxidation. This would result in membrane permeability 
alterations and allows the occurrence of intracellular cal- 
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cium accumulation and its deleterious consequences. Consis¬ 
tent with this is the fact that zinc has a membrane stabi¬ 
lizing effect probably by reducing free-radical induced mem¬ 
brane changes (24). 
Peroxidation of membrane lipids is a concept proposed 
by Meerson (36) to explain the pathogenesis of cardiac 
lesions caused by excess release of catecholamines in severe 
emotional and painful stress. This theory is based on a 
model of emotional and painful stress in which rats wait 
intensely for painful electric shocks for six hours and 
actually receive them at occasional intervals. Hearts were 
studied at various periods following termination of stress 
induction ranging from 2 hours to 4 days. Accumulation of 
hydroperoxides of lipids (products of lipid peroxidation) 
and labalization of lysomal enzymes occurred in those ani¬ 
mals subject to emotional/painful stress. Morphologically, 
there was hypercontraction and necrosis of myocardial fi¬ 
bers. Meerson suggested that the hydroperoxides of lipids 
and proteolytic lysosomal enzymes interfere with the mem¬ 
brane calcium transport apparatus and result in hvpercon- 
traction. In further experiments, he demonstrated that 
stress resulted in a significant decrease in capacity of 
sarcoplasmic reticulum membranes to accumulate calcium. 
This was thought to contribute to increased concentrations 
of calcium in the cytosol. Simultaneously, disturbances of 
oxidation and phosphorylation developed in mitochondria. 
Based on the above findings, Meerson proposed a theory 
of stress-induced cardiomyopathy. Emotional/painful stress 
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causes excitation of the higher vegetative centers which 
leads to an increased concentration of catecholamines in the 
blood. The catecholamines, in addition to acting on adreno¬ 
ceptors in the sarcolemma to activate adenylate cyclase, 
induce lipid peroxidation. These products (hydroperoxides) 
cause the release of proteolytic enzymes by lysis of lyso- 
somes. The action of both the lysosomal enzymes and hydro¬ 
peroxides of lipids results in damage to the sarcoplasmic 
reticulum membranes and sarcolemma. The mechanism for cal¬ 
cium transport is affected and excessive amounts of calcium 
accumulate in the cardiac cells causing what Meerson refers 
to as the "calcium triad." This includes contracture of 
myofibrils, damage to mitochondria with uncoupling of oxida¬ 
tion-phosphorylation, and activation of phospholipases and 
proteases. The result is hypercontraction and necrosis of 
myocardial fibers. 
With respect to norepinephrine-induced cardiomyopathy, 
Downing et al have demonstrated that short term (ninety 
minute) infusion of norepinephrine given in relatively mod¬ 
est doses (2 to 3 ug/kg/min) elicits a consistent pattern of 
myocardial injury in the rabbit (42). Measurements of car¬ 
diac function have revealed significant impairment of left 
ventricular performance when studied with afterload curves 
(65) or standard ventricular function curves (66). In 
studying the possible mechanisms of norepinephrine-induced 
injury, this group showed that insulin significantly reduced 
the extent of myofiber injury when rabbits were infused with 
norepinephrine (42). Previous studies in the isolated mus¬ 
cle preparation as well as the intact swine heart showed 
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that insulin substantially reduces contractility responses 
to norepinephrine (67,68). This indicates that there may 
exist a relationship between inotropic stimulation and cate¬ 
cholamine cardiomyopathy. Downing suggested that insulin 
may in larger doses exert other effects perhaps similar to 
the membrane stabalizing action of steroids. In a recent 
study (43) designed to assess the receptor system predomi¬ 
nantly involved in the pathogenesis of norepinephrine-in¬ 
duced lesions, Downing found that beta adrenergic blockade 
with practolol or propranolol failed to significantly reduce 
cardiac injury with norepinephrine. However, alpha adreno¬ 
ceptor blockade with phentolamine alone or in combination 
with either of the beta antagonists, markedly reduced lesion 
formation. Administration of the alpha agonist methoxamine 
produced dose-related increases in the intensity of myocar¬ 
dial injury morphologically identical with those resulting 
from norepinephrine. The alpha blocking agent, phentola¬ 
mine, markedly reduced methoxamine injury. Downing con¬ 
cluded that the norepinephrine cardiomyopathy results in 
large part from activation of the alpha adrenergic system in 
the rabbit model. He also speculated that alterations in 
myofiber calcium translocation, uptake, and binding induced 
by alpha-1 receptor activation may contribute to membrane 
damage. This is based on evidence for the existence of 
alpha receptors in cardiac muscle of several species, which, 
when activated, elicit inotropic changes. In contrast to the 
beta adrenergic system, activation of alpha receptors in¬ 
duces little reduction of time to peak tension, and relaxa- 
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tion time is lengthened, thus suggesting that altered myo¬ 
cardial calcium translocation is a primary event. 
While the exact mechanism of catecholamine-induced 
cardiomyopathy remains to be established, experimental evi¬ 
dence indicates a major role for membrane permeability al¬ 
terations leading to myocardial calcium overload. Ischemia 
due to coronary vasoconstriction appears unlikely to be an 
important pathogenetic mechanism. This is suggested by the 
fact that whereas catecholamines cause myocardial necrosis 
in the turtle, this species has no coronary arteries (52). 
Morever, the catecholamines probably do not evoke a net 
increase in myocardial oxygen demand (42,43) that might 
contribute to ischemia. The importance of calcium overload 
was suggested by investigations showing that verapamil pro¬ 
tects against isoproterenol and epinephrine-induced myocar¬ 
dial necrosis (40,48). The mechanism of verapamil protec¬ 
tion may be more complex than simple blockade of calcium 
influx, however. This is indicated by studies in which this 
agent also protected against isoproterenol-induced damage in 
parathyroidectomized rats. In this circumstance, myocardial 
calcium accumulation does not occur but myocyte injury does 
appear (48). It was therefore suggested that verapamil was 
acting through its negative inotropic and oxygen-sparing 
effects. However, this seems unlikely in view of the exper¬ 
imental evidence against the importance of ischemia in this 
process. The present study explores the question as to 
whether verapamil protects against norepinephrine-induced 
cardiomyopathy in the rabbit model, and examines the contri- 
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MATERIALS AND METHODS 
A total of 50 New Zealand white rabbits were used in 
this study. All animals were anesthetized with pentobarbi¬ 
tal, 30 mg/kg, and polyethylene catheters were placed in a 
femoral artery and vein. Arterial pressure was measured 
continuously with a Sanborn transducer, and heart rate was 
determined with a Sanborn cardiotachometer. The latter was 
verified by manual assessment of pulse frquency from pres¬ 
sure traces inscribed by a Sanborn recorder. Arterial blood 
samples were obtained at 15 minute intervals and analyzed 
for PO2, PCO2, and pH, with an Instrumentation Laboratories 
analyzer. Hematocrit and glucose concentrations (Glucostat, 
Worthington Biochemical) were also determined. 
The animals were divided into four groups. One group 
of thirteen rabbits was infused with norepinephrine (Levo- 
phed, Winthrop) at 2 ug/kg/min (NE-2) for ninety minutes. A 
second group of ten rabbits received a 50 ug loading dose of 
verapamil about five minutes before beginning infusion with 
NE-2 and verapamil at 1 ug/kg/min (VE-1) for 90 minutes. A 
third group of eight rabbits was also pretreated with 50 ug 
of verapamil five minutes prior to infusion with NE-2 and 
verapamil at 2 ug/kg/min (VE-2). Ten rabbits were treated 
with norepinephrine at 3 ug/kg/min (NE-3), and four were 
given NE-3 in combination with VE-2. A group of five control 
animals was infused with saline for ninety minutes. 
After infusion, the catheters were removed, the femoral 
wound surgically closed, and the animals returned to their 




standard rabbit chow diet and given water ad libitum. All 
animals were sacrificed 2 to 3 days later by overdose of 
pentobarbital via ear vein. The hearts were immediately 
removed, emptied, and weighed. The atria and right ventric¬ 
ular free wall were dissected and weighed, and the left 
ventricle and septum separately weighed. Transverse "ring" 
sections of left ventricles were obtained from the basal and 
mid-portions and fixed in 10% buffered formalin. They were 
prepared by standard histological methods and stained with 
hematoxylin and eosin for the subsequent analysis. 
Morphological evaluation employed a semiquantitative 
histological scoring system first described by Downing and 
Lee in 1978 (42). Each section was graded by 2 observers 
according to the extent and intensity of leukocytic response 
without prior knowledge of the procedures used in a given 
animal. A maximum score of 2.0 was given when the lesions 
were florid, extensive, and transmural. Those with definite 
but sparse lesions were scored 1.0. Equivocal focal lesions 
were scored 0.5. Those judged to manifest injury more 
extensive than 1.0, but less than 2.0 (e.g., nontransmural) 
were assigned a score of 1.5. A score of 0 was given when 
no histological abnormality was present. Values for each of 





DESCRIPTIVE RESULTS: The characteristic histologic findings 
in rabbits sacrificed 48 hours after a 90 minute infusion of 
norepinephrine at 3 ug/kg/min (NE-3) are shown in figure 1. 
This received a histological score of 2.0. There is an 
intense cellular infiltrate confined mostly to the intersti- 
tium especially in association with foci of myofiber necro¬ 
sis. The predominant cell population is mononuclear with 
large histiocytic cells being the most numerous accompanied 
by few lymphocytes. Polymorphonuclear cells including some 
eosinophils are occasionally present but in much smaller 
numbers. Extensive myofiber damage is present focally and 
numerous contraction bands and zones of granularity consis¬ 
tent with swollen mitochondria can also be seen. The Z 
lines are generally indistinct, and myofiber nuclei often 
are lost in the more active inflammatory foci. 
These changes characteristic of norepinephrine-induced 
damage were most pronounced in the inner half of the ven¬ 
tricular wall (subendocardial and mid-zonal portions), how¬ 
ever, transmural involvement was occasionally seen, espe¬ 
cially in those hearts exposed to higher doses of norepi¬ 
nephrine. The papillary muscles were uniformly involved but 
there did not appear to be a difference in intensity of free 
wall or septal involvement. With regard to the coronary 
vasculature, no discernible histopathological changes were 




Figure 2 shows a section typical of the verapamil 
treated animals. There are definite but sparse lesions with 
damage limited to the subendocardium. Scattered foci of 
myofiber necrosis, cellular infiltration, and vacuolization 
are seen. It was given a score of 1.0. Figure 3 was taken 
from a saline control and illustrates the normal histologic 
appearance of myocardium. 
QUANTITATIVE RESULTS: As described in the materials and 
methods section, basal and mid-level transverse slices from 
each heart were assigned an individual histologic score. 
All of the scores from a particular treatment group were 
averaged together into the overall score for that group. 
All groups treated with norepinephrine only exhibited 
significantly higher (p<0.05) histological scores than the 
saline control group. Average histologic scores of the 
norepinephrine and verapamil treatment groups are shown in 
figure 3. The value of the group treated with norepineph¬ 
rine at 2 ug/kg/min (NE-2) was 1.24 + 0.10 (S.E.). Treat¬ 
ment of the rabbits with a 50 ug loading dose of verapamil 
followed by infusion of verapamil at either 1 ug/kg/min or 2 
ug/kg/min (VE — 1; VE-2) simultaneously with NE-2 infusion 
resulted in a significant reduction in myocardial injury as 
shown by a score of 0.59 + 0.13 (p<0.01) in the VE-1 group, 
and 0.65 _+ 0.10 (p<0.01) in the VE-2 group. 
The 50 ug loading dose of verapamil followed by infu¬ 
sion of VE-2 also was protective against a higher dose of 
norepinephrine, i.e., 3 ug/kg/min infusion of norepinephrine 
(NE-3). As shown in figure 3, lower panal, the mean histo- 
-• 
41 
logic score of the NE-3 group was 1.44 + 0.13. Simultaneous 
infusion of NE-3 and VE-2 resulted in a significantly lower 
score of 0.69 + 0.21 (p<0.01). 
Figure 5 shows the relationship of norepinephrine and 
verapamil dosages to histologic scores. There does not 
appear to be a substantial increase in protection with a 
higher dose of verapamil as there was no significant differ¬ 
ence between the VE-1 and VE-2 groups (both of which were 
infused with NE-2). Also, the histologic score of the group 
given NE-3 along with VE-2 was not significantly different 
from the scores of the other two verapamil treated groups. 
The histologic scores of the NE-2 and NE-3 treatment groups 
were not significantly different from one another. 
HEMODYNAMIC AND METABOLIC RESPONSES TO NOREPINEPHRINE AND 
THE EFFECT OF VERAPAMIL INFUSION 
HEMODYNAMIC RESPONSES: Despite its protective effects 
against norepinephrine-induced histological damage, verapa¬ 
mil did not have a significant effect on the hemodynamic 
responses of the rabbit to norepinephrine. Figures 6 and 7 
show the mean arterial pressure (MAP), heart rate (HR), and 
MAP x HR (P x R) product responses of the various treatment 
groups. In the control animals, saline infusion did not 
result in any significant changes in MAP, HR, or P x R 
product. 
Figure 6 compares the hemodynamic responses of the NE-2 
group to the NE-2 + VE-2 group (as well as the saline con¬ 
trols). The NE-2 + VE-1 group showed basically similar 
trends in each parameter and was omitted from the figure for 
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the sake of clarity. Initial MAP just prior to the begin¬ 
ning the drug infusions was 94 +_ 5.0 (NE-2), 80 + 3.2 (NE-2 
+ VE-1), and 95 + 4.3 (NE-2 + VE-2). Initial HR was 249 + 
9.4 (NE-2), 243 + 4.5 (NE-2 + VE-1), and 254 + 9.1 (NE-2 + 
VE-2). Ten minutes after initiation of either norepineph¬ 
rine infusion or norepinephrine + verapamil infusion, MAP 
rose in all three groups to 128 + 5.6 (NE-2), 101 +_ 5.6 (NE- 
2 + VE-1), and 118 + 7.4 (NE-2 + VE-2). This was accom¬ 
panied by a reflex bradycardia as the HR dropped to 145 + 
12.3 (NE-2), 186 + 5.8 (NE-2 + VE-1), and 195 + 9.4 (NE-2 + 
VE-2). During the 90 minute infusion period, MAP gradually 
declined and HR increased toward baseline values. Ten min¬ 
utes after cessation of infusion, MAP had dropped below 
baseline values in all three groups to 62 _+ 3.2 (NE-2), 65 _+ 
4.6 (NE-2 + VE-1), and 72 + 3.4 (NE-2 + VE-2), while the 
mean HR had nearly reached baseline levels at values of 238 
+ 6.5 (NE-2), 231 + 9.4 (NE-2 + VE-1), and 253 + 12.1 (NE-2 
+ VE-2). 
Figure 7 illustrates the hemodynamic responses of NE-3 
and NE-3 + VE-2 treatment groups and shows basically the 
same pattern as described above with the MAP rising to a 
peak value at ten minutes after initiation of the infusion 
accompanied by reflex bradycardia. There followed a gradual 
decline in MAP towards baseline values and accompanying rise 
in HR, followed by a drop below baseline values by ten 
minutes after cessation of the infusion. 
It should be noted that all of the verapamil treated 
groups received a 50 ug loading dose of verapamil five 
minutes prior to beginning the infusion of norepinephrine 
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and verapamil. This resulted in a slight fall in MAP pre¬ 
sumably due to the vasodilating effects of verapamil on the 
peripheral vasculature with a reflex tachycardia (see fig¬ 
ures 6 and 7). 
In view of its vasodilating effects on the peripheral 
vasculature, it is conceivable that verapamil may protect 
the myocardium from norepinephrine-induced damage via reduc¬ 
tion of afterload. In order to assess this possibility, the 
effects of verapamil on MAP responses to norepinephrine were 
examined. Table 1 summarizes the blood pressure (BP) 
changes in the various groups at zero and ten minutes. It 
also shows the values for the difference between BP at ten 
minutes (the time at which maximal BP rise had occurred) and 
control BP and the difference between the integrated BP over 
the ninety minute infusion period and control BP. Initial 
BP of the NE-2 and NE-2 + VE-2 groups were essentially the 
same at values of 94 + 5.0, and 95 + 4.3 mmHg, respectively. 
The NE-2 + VE-1 group had a slightly lower initial BP of 80 
+ 3.2 (p<0.05). BP rose in all three groups ten minutes 
after initiation of infusion. While the two groups treated 
with verapamil attained lower absolute BP than the NE-2 
group, only the NE-2 + VE-1 was significantly lower at 101 + 
5.6 (p<0.01). This group also started out at a control BP 
that was about 15 mmHg lower than the other 2 groups. The 
NE-2 + VE-2 group had a BP at ten minutes of 118 + 7.4 which 
was not significantly different from the NE-2 group's BP of 
128 + 5.6. 
The change in BP from the control value to the ten 
■- 
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minute value was compared between the NE-2 group and the two 
verapamil treatment groups (Table 1). The rise in MAP in 
the verapamil treatment groups was lower than the NE-2 
group. However, there was no statistically significant 
difference between the NE-2 group and the NE-2 + VE-2 group 
which had rises in BP of 34 + 2.2 and 23 + 4.0 mmHg respec¬ 
tively at ten minutes. The NE-2 + VE-1 group had a smaller 
rise in BP of 21 +_ 5.9 mmHg (p<0.05). In rabbits treated 
with NE-3 or NE-3 + VE-2, the initial blood pressures were 
nearly identical at 102 + 4.8 and 100 + 3.3 mmHg, respec¬ 
tively. There was no statistically significant difference 
between the two groups in terms of the absolute BP achieved 
at ten minutes or the change in BP over ten minutes. 
The difference between initial BP and the average BP 
integrated over ninety minutes was also compared. There was 
no significant difference found between the NE-2 group and 
the NE-2 + VE-1 group or the NE-2 group and the NE-2 + VE-2 
groups. There was also no significant difference between 
the NE-3 and NE-3 + VE-2 groups. Thus, while verapamil 
treatment did appear to cause some blunting of the rise in 
MAP in response to norepinephrine infusion, this reduction 
in afterload was probably not enough to be a major factor in 
its protective effect on the myocardium. In support of this 
is the fact that the NE-2 + VE-2 and NE-3 + VE-2 had MAP 
values and changes in BP that did not differ significantly 
from their respective norepinephrine infusion groups, but 
exhibited significantly lower histologic damage scores. 
Also against the role of a certain absolute BP leading to 
myocardial damage is the fact that the BP at ten minutes 

45 
after initiation of infusion for the NE-3 + VE-2 group was 
higher than the BP of the NE-2 group (134 + 5.8 vs. 128 + 
5.6 mm Hg, respectively). Despite the tendency for a higher 
average BP (though the difference was not statistically 
significant), the histologic score of the NE-3 + VE-2 group 
was significantly lower than that of the NE-2 group (p 
<0.01). 
Further evidence against excessive hemodynamic loading 
as a main factor in norepinephrine-induced cardiac damage is 
presented in figures 8 and 9. In these figures, the rabbits 
in the NE-2 group are separated into 2 groups based on their 
histologic scores: those with scores less than or equal to 
1.0, and those with scores greater than or equal to 1.5. In 
figure 8, the maximum BP attained during the ninety minute 
infusion period is compared between the groups. Figure 9 is 
a comparison between the groups of the integrated mean BP 
over the ninety minute infusion period. There was no signi¬ 
ficant difference in maximum BP between the high score and 
low score groups which had maximum BP’s of 134 + 5.9 and 123 
+ 9.6 mmHg respectively. There was also no significant 
difference in the integrated BP over the ninety minute 
infusion period between the groups. The high score groups 
had an integrated BP of 116 +_ 5.2 mmHg, and the low score 
had a value of 107 _+ 7.7 mmHg. 
CARDIAC METABOLIC DEMAND: The MAP X HR (P x R) product for 
each group is shown in the lowermost panels of figures 6 and 
7; and values at 0, 10, 30, 60, and 90 minutes are summa¬ 
rized in table 2. For all the groups, the P x R remained 
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nearly constant throughout the infusion and in no instance 
was the initial control value exceeded. The initial values 
(x103) were 29 .3 + 1.8 (saline controls), 23 .7 + 1.8 (NE- 2), 
and 25 
+
 1 1.8 (NE- 3) . The P x R values at 0, 10, 30, 60 , 
and 90 minutes f or the saline controls were compared to the 
NE-2 and NE -3 group s. The P x R values for the NE-3 groups 
did not differ significantly from the saline cntrols, while 
the P x R values for the NE-2 group did not differ signifi¬ 
cantly from the saline controls except at the 60 and 90 
minute points where the NE-2 P x R product was significantly 
lower (p<0.0l). At no point did the P x R product of either 
norepinephrine group rise or exceed the values of the saline 
controls. Thus, it appears unlikely that excessive meta¬ 
bolic demand was a significant factor in the pathogenesis of 
the myocardial lesions caused by norepinephrine. Further¬ 
more, when the P x R product at each interval was compared 
between the norepinephrine infusion groups and the norepi¬ 
nephrine + verapamil infusion groups, the only statistically 
significant difference was between the control P x R product 
of NE-2 + VE-1 which was lower than that of NE-2 (p<0.05). 
However, this value was obtained prior to the infusion of 
verapamil + norepinephrine. Thus, verapamil treatment did 
not result in significantly lower P x R products, and there¬ 
fore it is unlikely that verapamil could have exerted its 
protective effect by decreasing metabolic demand. 
■ 
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ARTERIAL pH, BLOOD GASES, SERUM GLUCOSE, AND HEMATOCRIT 
CHANGES 
The pH in all treatment groups showed a tendency to¬ 
wards a slight decrease during the infusion followed by 
return to baseline values ten minutes after the infusion was 
stopped. This may be a reflection of a slight respiratory 
acidosis which is indicated by the increase in pC02 values 
that occurred in all five treatment groups during the infu¬ 
sion period. There was a return towards baseline values ten 
minutes after cessation of the infusion. In contrast, the 
saline controls exhibited a slight rise in pH which was 
probably a result of the slight fall in pCC>2 values during 
the infusion period. Arterial pC>2 values in all five treat¬ 
ment groups showed minimal change during the infusion period 
with only a slight increase observed ten minutes after 
cessation of infusion. 
Figures 10 and 11 show the plasma glucose values of all 
the groups. It can be seen that the dramatic rise in plasma 
glucose caused by norepinephrine infusion was unaltered by 
simultaneous infusion of verapamil. The curves for all 
treatment groups show nearly identical rises in plasma glu¬ 
cose in contrast to the flat saline control curves. The 
plasma glucose in the NE-2, NE-2 + VE-1, and NE-2 + VE-2 
groups rose progressively from about 168 mg/dl to a maximum 
value of about 375 mg/dl ten minutes after cessation of 
infusion. The NE-3 and NE-3 + VE-2 groups had an initial 
plasma glucose of about 123 mg/dl, which rose to a maximum 
of about 371 mg/dl. The saline controls showed minimal 
changes in serum glucose during infusion and averaged about 
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155 mg/dl . 
The hematocrit values of all groups are also shown in 
figures 10 and 11. The norepinephrine and verapamil treat¬ 
ment groups showed an average drop in hematocrit of about 
4%, presumably due to hemodilution by fluid infusion. This 
probably was not physiologically significant. Thus, the 
changes in the measured physiological parameters induced by 





The results of this study indicate that verapamil is 
capable of reducing the severity of norepinephrine-induced 
cardiomyopathy. It was found that administration of VE-1 or 
VE-2 simultaneously with NE-2 significantly reduced the 
histologic score from 1.24 to 0.59 (VE-1) and 0.65 (VE-2). 
The VE-2 infusion was also protective against a higher dose 
of norepinephrine (3 ug/kg/min) reducing the score from 1.44 
to 0.69. There did not appear to be an increased amount of 
protection with a higher dose of verapamil as the scores of 
the VE-1 and VE-2 groups were not significantly different. 
All of the verapamil treated animals received a 50 ug bolus 
of verapamil prior to the infusion to rapidly achieve a 
therapeutic level which could be maintained by the infusion. 
These findings are in agreement with previous studies 
which showed that verapamil is able to reduce the myocardial 
damage caused by catecholamines (48,69). Fleckenstein (69), 
in a review of his studies of catecholamine cardiomyopathy, 
cited a experiment in which he demonstrated that verapamil 
was capable of protecting the rat heart against structural 
damage if given in appropriate dosage (50 mg/kg) simulta¬ 
neously with isoproterenol (30 mg/kg) subcutaneously. Based 
on a number of studies involving myocardial uptake of ra¬ 
dioactive calcium, Fleckenstein found that subcutaneous 
administration of 30 mg/kg of isoproterenol resulted in an 
increase in the uptake of ^^Ca^+ by a factor of six to ten 
with a maximum level in six hours. Simultaneous administra¬ 
tion of verapamil significantly inhibited the excessive 
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isoproterenol-induced radiocalcium uptake. Fleckenstein 
also described experiments in which verapamil (50 mg/kg) was 
effective in inhibiting the isoproterenol-induced breakdown 
of creatine phosphate fraction in the left ventricular myo¬ 
cardium of rats. Based on these data, he attributed the 
protective effect of verapamil against isoproterenol to its 
calcium channel blocking abilities by preventing calcium 
overload induced by high doses of catecholamines. The latter 
initiates breakdown of ATP and creatine phosphate leading to 
high-energy phosphate exhaustion via activation of the cal¬ 
cium dependent myofibrillar ATPase responsible for trans¬ 
forming phosphate bond energy into mechanical work. 
The mechanism of verapami1-indueed protection is proba¬ 
bly not due simply to its calcium channel blocking activi¬ 
ties to prevent high-energy phosphate depletion. Lehr (48), 
in a review of his studies on catecholamine cardiomyopathy 
found that verapamil was protective against isoproterenol . 
But he also found that verapamil was equally effective in 
parathyroidectomized rats in which myocardial calcium accu¬ 
mulation does not occur. Parathyroidectomy alone does not 
protect against isoproterenol-induced injury. Based on 
these findings, he concluded that calcium overloading is not 
a mechanism directly responsible for the cardiac injury 
produced by catecholamines, and that the beneficial effect 
of verapamil is based on a property other than the preven¬ 
tion of ATP depletion by calcium dependent ATPases. He 
suggested that verapamil may be protective via an oxygen 




Lehr also found that identical myocardial injury could 
be produced by phenylephrine, an alpha adrenergic agonist, 
and that verapamil protected against myocardial necrosis 
elicited by this drug. He postulated that at cardiotoxic 
doses, epinephrine acts primarily as an alpha adrenergic 
agonist. Thus, rats pretreated with theophylline, which 
inhibits cAMP breakdown by phosphodiesterase, show aggra¬ 
vated myocardial injury induced by isoproterenol. But myo¬ 
cardial injury induced by both phenylephrine and epinephrine 
are significantly reduced. This was based on the assumption 
that the stimulation of adenylate cyclase with subsequent 
formation of cAMP is a mechanism specific for beta, and not 
alpha receptors. Beta blockade with propranolol prevented 
isoproterenol-induced injury but had no effect on damage 
caused by phenylephrine. It was only marginally effective 
against tissue damage by epinephrine. Furthermore, alpha 
blockade significantly inhibited the development of epineph¬ 
rine-induced necrosis. He suggested that ischemia may be a 
common denominator in myocardial necrosis elicited by alpha 
and beta adrenergic amines but that alpha agonists create a 
myocardial oxygen debt. This likely results from enhance¬ 
ment of the workload resulting from increased peripheral 
resistance (hypertension), probably in the face of impeded 
blood supply to the myocardium due to coronary vasocon¬ 
striction. In contrast, beta agonists cause ischemia by a 
combination of reduced coronary blood flow (CBF) from hypo¬ 
tension, and oxygen wastage by the intense positive inotro¬ 
pic and chronotropic effects of excessive stimulation of 
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myocardial beta receptors. 
Norepinephrine, like epinephrine, also has both alpha 
and beta adrenergic activities, and Downing et al (43) 
demonstrated a major role of the alpha adrenergic system in 
norepinephrine-induced cardiomyopathy. They found that beta 
adrenergic blockade with practolol or propranolol failed to 
significantly reduce cardiac injury with norepinephrine. 
However, alpha receptor blockade with phentolamine markedly 
reduced lesion formation by norepinephrine. Furthermore, 
administration of the alpha agonist, methoxamine, produced 
myocardial injury which was morphologically identical to 
that of norepinephrine. Phentolamine sharply reduced meth- 
oxamine-induced myocardial injury. Arterial pressure and 
heart rate changes caused by methoxamine were the same as 
those caused by norepinephrine. In both norepinephrine and 
methoxamine treated animals, phentolamine prevented the rise 
in arterial pressure and reduced the extent of reflex car¬ 
diac slowing. 
According to Lehr's theory, alpha agonists induce myo¬ 
cardial injury by causing ischemia. This is secondary to 
increased peripheral vascular resistance and probably im¬ 
paired blood supply to the myocardium due to coronary vaso¬ 
constriction. Verapamil acts via its oxygen sparing effect, 
by reducing metabolic demand and afterload, thereby protect¬ 
ing the myocardium from the damaging effects of norepineph¬ 
rine. The results of the present study indicate that these 
two mechanisms are probably unlikely. The P x R product 
(blood pressure x heart rate) has been shown to be the 
hemodynamic parameter that correlates best with myocardial 
■ 
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oxygen consumption (r = 0.86) (70). However, verapamil did 
not significantly lower the P x R product at any time during 
norepinephrine infusion in this study. This is in agreement 
with previous observations in patients with ischemic heart 
disease in which the administration of verapamil had no 
significant effect on MVO2 (71,72). It suggests that vera¬ 
pamil does not exert its protective effects by decreasing 
metabolic demand. In addition, this study confirms previous 
findings that norepinephrine infusion does not result in an 
increase in metabolic demand (43,73). The NE-2 and NE-3 
groups had P x R products that at no point rose or exceeded 
the values obtained in the saline controls. Thus, it is 
unlikely that excessive metabolic demand plays a major role 
in norepinephrine-induced cardiomyopathy. 
Another way in which verapamil might decrease norepi¬ 
nephrine-induced damage is via afterload reduction. It is 
well established that verapamil has profound vasodilatory 
effects on vascular smooth muscle, especially the arteriolar 
beds (74). The present study showed a slight drop in sys¬ 
temic blood pressure five minutes after administration of 
the loading dose of verapamil. However, if verapamil was to 
protect against the effects of norepinephrine by reducing 
peripheral resistance, it should be expected to significant¬ 
ly diminish the rise in systemic blood pressure. This 
mechanism appears unlikely because in the verapamil treated 
groups, hemodynamic parameters followed the same patterns as 
the norepinephrine treated groups. Blood pressure rose to a 
peak value about ten minutes after initiation of the infu- 
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sion and this was accompanied by a reflex bradycardia. This 
was followed by a gradual decline in blood pressure towards 
baseline values and an accompanying rise in heart rate. 
While the blood pressure rise and absolute blood pressure at 
ten minutes was slightly lower in the verapamil treatment 
groups, the differences were not significant between the NE- 
2 + VE-2 and NE-2 groups, or between the NE-3 + VE-2 and NE- 
3 groups. Morever, when the average rise in blood pressure 
over the ninety minute period was compared between the 
norepinephrine treatment groups and the verapamil treatment 
groups, no significant differences were found. Thus, it 
seems probable that the slight reduction in the norepineph¬ 
rine-induced rise in blood pressure caused by verapamil was 
not a major factor in the protective effect of verapamil. 
While both the NE-2 + VE-2 and NE-3 + VE-2 groups 
exhibited blood pressure alterations that did not differ 
significantly from their respective norepinephrine treatment 
groups, the verapamil treated rabbits had significantly 
lower histological scores. Furthermore, the absolute blood 
pressure attained after ten minutes of infusion for the NE-3 
+ VE-2 groups tended to be higher than that attained by the 
NE-2 group (though not statistically significant). But the 
histological score of the NE-3 + VE-2 group was sharply 
lower than that of the NE-2 group (pcO.Ol). Further evi¬ 
dence against excessive hemodynamic loading as an important 
mechanism in norepinephrine-induced cardiomyopathy was ob¬ 
tained by comparing the maximum blood pressure and the inte¬ 
grated blood pressure over ninety minutes in a high histo¬ 
logical score group (greater than or equal to 1.5) and a low 
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score group (less than or equal to 1.0). No difference was 
demonstrated by either analysis. 
Lehr (48) also suggested a possible pathogenetic role 
of impaired blood supply to the myocardium caused by coro¬ 
nary vasoconstriction. Simons (73) recently found that 
norepinephrine causes an increase in coronary blood flow 
(CBF) in the rabbit from 2.66 ml/g/min initially to 3.46 
after three minutes of norepinephrine infusion (p<0.05). 
CBF declined to baseline values (2.33) after ten minutes, 
but showed a sharp decline to 1.51 after forty minutes of 
infusion. Coronary resistance (CR) rose progressively from 
baseline values of 40.9 units to 74.8 at forty minutes 
(p<0.05). Animals given phentolamine manifested none of 
these changes in CBF and CR and also had significantly less 
norepinephrine-induced damage compared to norepinephrine 
alone (p<0.01). He concluded that norepinephrine induces 
sustained coronary vasoconstriction in the rabbit and that 
reduced CBF may contribute to the pathogenesis of norepi¬ 
nephrine cardiomyopathy in the rabbit. Since it is well 
established that the coronary bed is exquisitely sensitive 
to the vasodilating effects of calcium channel blockers 
(75) , it is possible that verapamil exerts a protective 
effect via this mechanism. These agents exert a potent 
coronary vasodilator effect in the isolated rabbit heart 
(76) . In dogs, CBF increases and CR decreases, though no 
change occurs in the caliber of the large coronary arteries. 




While stimulation of alpha receptors to induce coronary 
vasoconstriction may contribute to norepinephrine-induced 
cardiomyopathy, the possible role of myocardial alpha recep¬ 
tors must also be considered. The calcium channel blockers 
have recently been found to have alpha receptor blocking 
properties. Hence, this is another mechanism by which vera¬ 
pamil may exert its protective effects. In a recent review, 
Benfey (78) summarized studies which show that myocardial 
alpha receptors alter myocardial contractility. Alpha re¬ 
ceptor mediated positive inotropic effects have been ob¬ 
served in isolated heart preparations from animals and hu¬ 
mans (79). In the absence of beta receptor blockade, alpha 
blockade with phentolamine potentiates the inotropic effect 
of epinephrine and norepinephrine on rat ventricle strips. 
In the presence of beta blockade, however, it inhibits the 
effect of the catecholamines (80). Phentolamine, and not 
propranolol, inhibits the inotropic effect of low concentra¬ 
tions of epinephrine and phenylephrine in rabbit atrium 
(81). Methoxamine in suitable concentrations elicits sub¬ 
stantial increases in force development in rat right ven¬ 
tricular papillary muscle and rat atrium (82,83). Methoxa¬ 
mine elicits dose-related increases of left ventricular 
contractility in the lamb as well (84). Aass et al (85) 
demonstrated that the myocardial alpha receptors in rabbit 
heart ventricle can be activated by norepinephrine to pro¬ 
duce an inotropic effect. However, beta blockade with pro- 
panolol was required to unmask the alpha response. These 
effects were eliminated by alpha-1 blockade with prazosin. 
In view of these several findings, it is likely that norepi- 
. 
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nephrine-induced cardiomyopathy involves activation of the 
myocardial alpha receptor system. 
Recent studies have indicated that selected calcium 
channel blockers, notably verapamil, are capable of antagon¬ 
izing binding to myocardial alpha receptors (86-90). Both 
Endoh et al (86) and Siegl (91) have shown that D600 (the 
methoxy derivative of verapamil) inhibits alpha adrenocep¬ 
tor-mediated positive inotropic effects of phenylephrine. 
Sensitivity to isoproterenol was only partly inhibited, with 
no decrease in maximal effect. It is interesting to note 
that Motulsky et al (89) found that of all the calcium 
channel blockers, only verapamil and its analogues could 
block binding to alpha receptors. They attributed this to 
its greater structural similarity to epinephrine than other 
calcium channel blockers such as nifedipine or diltiazem. 
There also exists wide species variability in myocardial 
adrenergic receptor numbers. Mukherjee et al (90) found 
markedly decreased numbers of alpha and increased numbers of 
beta receptors in the canine as compared to rabbit or rat 
myocardium. They also found differences in the degree to 
which various calcium channel blockers competed with alpha 
antagonists for binding in different species. Notably, only 
in rabbit myocardium does verapamil antagonize alpha recep¬ 
tor binding at moderate concentrations (half maximal binding 
value of 5 x 10"7 M) whereas verapamil in canine and rat 
myocardium, and D600 in all three species antagonize alpha 
receptors only at relatively high concentrations. Thus, it 
is likely that verapamil exerts a protective effect against 
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norepinephrine-induced cardiomyopathy in the rabbit by inhi¬ 
biting activation of the myocardial alpha receptor system. 
The calcium channel blocking effects of verapamil may 
also be an important mechanism. Influx of calcium is likely 
involved in the inotropic effects of alpha receptors. Alpha 
receptors, in contrast to beta receptors, induce little 
reduction of time to peak tension, and relaxation time is 
lengthened. These mechanical events are consistent with 
stimulation by calcium ions. Indeed, altered calcium trans¬ 
location may be a final common pathway of cell death (42). 
It has been recently suggested that accelerated calcium- 
induced membrane damage may be an important mechanism in the 
sequence of cell death (92,93). Regardless of the type of 
initial injury (ischemic or "toxic" damage), the myocyte 
undergoes calcium accumulation, either by impaired energy 
metabolism and/or by plasma membrane alterations. Elevated 
intracellular calcium concentrations are responsible for 
cytoskeletal modifications that alter cell shape, activate 
phospholipases that perpetuate membrane damage, and finally 
lead to mitochondrial calcification. The relationship of 
norepinephrine-induced cardiomyopathy to this scheme is of 
course speculative. But it represents a potential mechanism 
through which verapamil may act to interrupt calcium-induced 
injury. 
In summary this study has demonstrated that verapamil 
causes a substantial reduction in the severity of damage to 
the myocardium caused by norepinephrine. It appears unlike¬ 
ly that verapamil exerts its protective effects via reduc¬ 
tions in afterload or metabolic demand because hemodynamic 
' 
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responses to norepinephrine were unaltered and there was no 
significant decrease in the P x R product. There are sever¬ 
al possible mechanisms by which verapamil may exert its 
protective effects. These include prevention of norepineph¬ 
rine-induced coronary vasoconstriction, inhibition of myo¬ 
cardial alpha receptor activation, and prevention of lethal 
calcium accumulation within the cell. The latter is likely 
the common pathway of cell death regardless of the initial 
mechanism of injury. Indeed, verapamil may act at each of 
these sites. Further studies will be required to elucidate 
more precisely the individual mechanisms by which verapamil 
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Representative histologic (H & E stain) section 
tricular myocardium from a rabbit sacrificed 48 
a ninety minute infusion of norepinephrine at 3 
There is extensive leukocytic infiltration, 
band formation, and focal myofiber damage char- 
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FIGURE 2. Representative histologic (H & E stain) section 
of left ventricular myocardium from rabbit sacrificed 48 
hours after simultaneous infusion with verapamil at 1 
ug/kg/min and norepinephrine at 2 ug/kg/min for ninety min¬ 
utes. There are definite but sparse lesions with damage 
limited to the subendocardium and less extensive necrosis, 
cellular infiltrate, and vacuolization characteristic of 
lesions scored 1.0. Original magnification 200X. 
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FIGURE 4. Histological scores from hearts in various groups 
of rabbits infused with norepinephrine only (NE) or NE 
simultaneously with verapamil (VE). Numbers in parentheses 
indicate ug/kg/min for NE and VE. Numbers within columns 
represent the number of animals in each group. Values are 
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FIGURE 5. Relationship of norepinephrine (NE) and verapamil 
(VE) dosages to histological score. Numbers in parentheses 
indicate ug/kg/min for NE and VE. C = control group of 
saline infused rabbits. Values are expressed as mean histo¬ 





FIGURE 6. Values of the mean arterial pressure (MAP), heart 
rate (HR), and pressure-rate product (MAP X HR) at desig¬ 
nated intervals before, during, and following norepinephrine 
(NE), NE + verapamil (VE), or saline (C) infusion. Numbers 
in parentheses indicate ug/kg/min for NE and VE. A 50 ug 
loading dose of VE was given five minutes prior to beginning 
infusion with NE and VE as indicated. Values are expressed 
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FIGURE 7. Values of the mean arterial pressure (MAP), heart 
rate (HR), and pressure-rate product (MAP X HR) at desig¬ 
nated intervals before, during, and following norepinephrine 
(NE), NE + verapamil (VE), or saline (C) infusion. Numbers 
in parentheses indicate ug/kg/min for NE and VE. A 50 ug 
loading dose of VE was given five minutes prior to beginning 
infusion with NE and VE as indicated. Values are expressed 













HISTOLOGICAL SCORES (units) 
FIGURE 8. Comparison of the average maximum blood pressure 
(BP) attained during infusion with norepinephrine alone at 2 
ug/kg/min for ninety minutes by rabbits with histological 
scores less than or equal to 1.0 and those with scores 
greater than or equal to 1.5. NS indicates non-significance. 




















HISTOLOGICAL SCORES (units) 
FIGURE 9. Comparison of the average integrated mean blood 
pressure (BP) over the ninety minute infusion period with 
norepinephrine at 2 ug/kg/min of rabbits with histologic 
scores less than or equal to 1.0 and those with scores 
greater than or equal to 1.5. NS indicates non-signifi¬ 
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FIGURE 10. Mean values for plasma glucose and hematocrit at 
designated intervals before, during, and following norepi¬ 
nephrine (NE), NE + verapamil (VE), or saline (C) infusion. 
Numbers in parentheses indicate ug/kg/min for NE and VE. A 
50 ug loading dose of VE was given five minutes prior to 
beginning infusion with NE and VE as indicated. Values are 
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FIGURE 11. Mean values for plasma glucose and hematocrit at 
designated intervals before, during, and following norepi¬ 
nephrine (NE), NE + verapamil (VE), or saline (C) infusion. 
Numbers in parentheses indicate ug/kg/min for NE and VE. A 
50 ug loading dose of VE was given five minutes prior to 
beginning infusion with NE and VE as indicated. Values are 




BLOOD PRESSURE CHANGES IN RESPONSE TO VARIOUS AGENTS INDICATED 
MEAN ARTERIAL PRESSURE (mmHg + S.E.) 
CONTROL BP BP(10) BP(10)-BP(C) INT.BP-BP(C) n 
NE-2 94+5.0 128+5.6 34+2.2 18+2.1 13 
NE-2VE-1 80+3.2a 101+5.6° 21+5.9b 16+3.8 10 
NE-2VE-2 95+4.3a 118 + 7.4 23 + 4.0 14+2.6 8 
NE-3 102+4.8 139+4.9 37+2.6 22+2.2 10 
NE-3VE-2 100+3.3a 134+5.8 34+3.6 25+2.4 4 
SALINE 102+6.0 103+7.9 0.6 + 2.1 1 + 1.6 5 
a five minutes post 50 ug loading dose of verapamil 
b P < 0.05 
c P < 0.01 
TABLE 1. Mean arterial pressure changes during ninety minute 
infusion of the treatment combinations of norepinephrine and 
verapamil indicated. Control BP = control blood pressure (prior 
to initiation of infusion). BP(10) = mean arterial pressure ten 
minutes after beginning infusion of drugs indicated. BP(10)- 
BP(C) = the difference between the blood pressure at ten minutes 
and control blood pressure. INT. BP - BP(C) = the difference 
between the integrated blood pressure over the ninety minute 
infusion period and control blood pressure. n = number of rab¬ 
bits. NE-2, NE-3 = infusion of norepinephrine at 2 ug/kg/mg and 
3 ug/kg/min, respectively. VE-1, VE-2 = infusion of verapamil at 




EFFECT OF THE VARIOUS TREATMENT COMBINATIONS OF NOREPINEPHRINE 
AND VERAPAMIL ON CARDIAC METABOLIC DEMAND 
P X R PRODUCT (X 103 + S.E.) 
CONTROL 10 MIN 30 MIN 60 MIN 90 MIN n 
SALINE 29.3+1.8 28.7+1.9 26.7+1.9 25.6+1.5 25.9+0.9 5 
NE-2 23.7+1.8 19.0+2.1 19.3+1 .8 16.7+1.6b 16.7+1.4b 13 
NE-3 25.7+1.8 23.7+3.5 23.0+2.5 22.6+2.1 20.9+1.7 10 
NE-2 23.7+1.8 19.0 + 2.1 19.3+1.8 16.7+1.6 16.7+1.4 13 
NE-2VE-1 19.5 + J_. 0 a 18.6+0.9 16.8+1.0 16.6+0.8 16.3+0.8 8 
NE-2VE-2 24.1+1.5 22.6+1.2 20.9+0.8 19.7 + 0.8 19.3+0.9 10 
NE-3 25.7+1.8 23.7+3.5 23.0+2.5 22.6+2.1 20.9+1.7 10 
NE-3VE-2 28.6+0.9 27.7+0.8 25. 1 + 1.5 22.1+1.2 23.4+2.0 4 
a P < 0.05 
b P < 0.01 
TABLE 2. The effect of the various treatment combinations of 
norepinephrine and verapamil on cardiac metabolic demand. Card¬ 
iac metabolic demand is represented by the P X R product (X 103 + 
S.E.) of each treatment group at 0 minutes (control), 10 minutes, 
30 minutes, 60 minutes, and 90 minutes after beginning infusion 
of the agent(s) indicated. P X R = the product of mean arterial 
pressure and heart rate. n = number of rabbits. NE-2, NE-3 = 
infusion of norepinephrine at 2 ug/kg/min and 3 ug/kg/min, re¬ 
spectively. VE-1, VE-2 = infusion of verapamil at 1 ug/kg/min 
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